article · RSC Advances
A green spectrofluorimetric technique has been established to quantify the antidepressant drug fluvoxamine in pharmaceutical tablets. The method uses an association complex formed between fluvoxamine and erythrosine B within an acetate buffer solution. Fluvoxamine quenches the natural fluorescence of erythrosine B at 552 nm following excitation at 530 nm. Under optimal conditions, the degree of quenching is linear across a concentration range of 0.2 to 2.0 micrograms per millilitre. The analytical approach was validated following International Council for Harmonisation guidelines, achieving a detection limit of 0.03 micrograms per millilitre. It was successfully applied to measure the drug in commercial dosage forms with an average recovery of 98.92 percent, showing no interference from common excipients, and was successfully used for pharmaceutical content uniformity testing.
Ensuring that pharmaceutical tablets contain the correct dosage of active ingredients is vital for patient safety and drug efficacy. This method provides an environmentally friendly, reliable, and straightforward alternative for quality control testing of fluvoxamine tablets, verifying that individual tablets meet required standards without interference from typical inactive tablet components.
The method is applied and tested directly on pharmaceutical tablet forms and content uniformity testing according to international validation standards. Potential users include pharmaceutical quality control laboratories, contract analytical testing facilities, and regulatory compliance units. Given that the protocol has been validated on finished dosage forms, it appears near-market for integration into routine pharmaceutical quality assurance workflows.
AI-generated from the published abstract. Always read the original work before citing.
A green-complied spectrofluorimetric approach for quantification of the antidepressant, fluvoxamine, has been established. The method that has been suggested relies on the development of an association complex between fluvoxamine and erythrosine B in an acetate buffer solution. After being excited at 530 nm, the quenching in erythrosine B's native fluorescence caused by complex formation with fluvoxamine was detected at a wavelength of 552 nm. The values of fluorescence quenching at the most optimal reaction conditions were rectilinear at the concentration range of 0.2-2.0 μg mL<sup>-1</sup>, with a good correlation coefficient (<i>r</i> = 0.9998). The detection limit for the method was 0.03 μg mL<sup>-1</sup> while the quantitation limit was 0.09 μg mL<sup>-1</sup>. The suggested approach has been validated according to the ICH. The established approach was effectively used to determine the drug under study in its dosage form with an average percent recovery of 98.92 ± 0.87 (<i>n</i> = 5), with no effect caused by the existing excipients. The proposed approach was also successfully used for the content uniformity test.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1039/d3ra08257a
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
